1
|
Papadopoulos K, Li T, Lakhani N, Powderly J, George T, Teoh D, Kilari D, Giaccone G, Sanborn R, Ghamande S, LoRusso P, Gibney G, Ma VL, Yalamanchili K, Brown J, Mota N, Tasillo Kadra C, Umiker B, Xiao X, Trehu E. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
2
|
Sacher A, Patel M, Miller W, Desai J, Garralda E, Bowyer S, Kim T, De Miguel M, Falcon A, Krebs M, Lee J, Cheng M, Han SW, Shacham-Shmueli E, Forster M, Jerusalem G, Massarelli E, Paz-Ares Rodriguez L, Prenen H, Walpole I, Arbour K, Choi Y, Dharia N, Lin M, Mandlekar S, Royer Joo S, Shi Z, Schutzman J, LoRusso P. OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Chung H, Lee K, Kim W, Gainor J, Lakhani N, Chow L, Messersmith W, Fanning P, Squifflet P, Jin F, Forgie A, Wan H, Pons J, Randolph S, LoRusso P. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Wainberg Z, Matos I, Delord J, Cassier P, Gil-Martin M, Kim T, LoRusso P, Bahleda R, Italiano A, Mendus D, Hoang T, Xue C, Wen X, Carvalho O, Pham T, Patil N, Meng R, Bendell J, Cervantes A, Cho B. LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.06.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Carducci M, Wang D, Habermehl C, Bödding M, Rohdich F, Stinchi S, Karpenko O, Gimmi C, LoRusso P. 566P A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
6
|
Wang J, Barve M, Chiorean E, LoRusso P, Courtney K, Qi D, Bullington J, Sardone M, Chen J, Brooks C, Hoberman M, Mughal T, Bauer T. 564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Puzanov I, Havenith K, Boni J, Cruz H, Anderson K, Kopotsha T, Le Bruchec Y, Bendell J, Kummar S, Papadopoulos K, LoRusso P, Wuerthner J. 1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol 2020; 31:590-598. [PMID: 32245699 DOI: 10.1016/j.annonc.2020.02.008] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 02/05/2020] [Accepted: 02/12/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to prevent or overcome treatment failure. PATIENTS AND METHODS We obtained tumor biopsies from metastatic breast cancer patients with BRCA1/2 deficiency before and after acquired resistance to PARPi or platinum chemotherapy. Whole exome sequencing was carried out on each tumor, germline DNA, and circulating tumor DNA. Tumors underwent RNA sequencing, and immunohistochemical staining for RAD51 foci on tumor sections was carried out for functional assessment of intact homologous recombination (HR). RESULTS Pre- and post-resistance tumor samples were sequenced from eight patients (four with BRCA1 and four with BRCA2 mutation; four treated with PARPi and four with platinum). Following disease progression on DNA-damaging therapy, four patients (50%) acquired at least one somatic reversion alteration likely to result in functional BRCA1/2 protein detected by tumor or circulating tumor DNA sequencing. Two patients with germline BRCA1 deficiency acquired genomic alterations anticipated to restore HR through increased DNA end resection: loss of TP53BP1 in one patient and amplification of MRE11A in another. RAD51 foci were acquired post-resistance in all patients with genomic reversion, consistent with reconstitution of HR. All patients whose tumors demonstrated RAD51 foci post-resistance were intrinsically resistant to subsequent lines of DNA-damaging therapy. CONCLUSIONS Genomic reversion in BRCA1/2 was the most commonly observed mechanism of resistance, occurring in four of eight patients. Novel sequence alterations leading to increased DNA end resection were seen in two patients, and may be targetable for therapeutic benefit. The presence of RAD51 foci by immunohistochemistry was consistent with BRCA1/2 protein functional status from genomic data and predicted response to later DNA-damaging therapy, supporting RAD51 focus formation as a clinically useful biomarker.
Collapse
Affiliation(s)
- A G Waks
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - O Cohen
- Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - B Kochupurakkal
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA
| | - D Kim
- Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - C E Dunn
- Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA
| | - J Buendia Buendia
- Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - S Wander
- Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA
| | - K Helvie
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - M R Lloyd
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; University of Massachusetts Medical School, Worcester, USA
| | - L Marini
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA
| | - M E Hughes
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - S S Freeman
- Broad Institute of MIT and Harvard, Cambridge, USA
| | - S P Ivy
- Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA
| | - J Geradts
- City of Hope Comprehensive Cancer Center, Duarte, USA
| | - S Isakoff
- Harvard Medical School, Boston, USA; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, USA
| | | | | | - S M Tolaney
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - U Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - I E Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - A D D'Andrea
- Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
| | - E P Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - N U Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - G I Shapiro
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA
| | - N Wagle
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
| |
Collapse
|
9
|
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 2019; 29:1561-1568. [PMID: 29726923 DOI: 10.1093/annonc/mdy171] [Citation(s) in RCA: 82] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Background Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, immunogenicity and preliminary efficacy of brontictuzumab in patients with solid tumors. Patients and methods Subjects with selected refractory solid tumors were eligible. Brontictuzumab was administered intravenously at various dose levels and schedule during dose escalation, and at 1.5 mg/kg every 3 weeks (Q3W) during expansion. Evidence of Notch1 pathway activation as determined by an immunohistochemistry assay was required for entry in the expansion cohort. Adverse events were graded according to the NCI-CTCAE v 4.03. Efficacy was assessed by RECIST 1.1. Results Forty-eight subjects enrolled (33 in dose escalation and 15 in the expansion phase). The MTD was 1.5 mg/kg Q3W. Dose-limiting toxicities were grade 3 diarrhea in two subjects and grade 3 fatigue in one subject. The most common drug-related adverse events of any grade were diarrhea (71%), fatigue (44%), nausea (40%), vomiting (21%), and AST increase (21%). Brontictuzumab exhibited nonlinear pharmacokinetics with dose-dependent terminal half-life ranging 1-4 days. Clinical benefit was seen in 6 of 36 (17%) assessable subjects: 2 had unconfirmed partial response (PR) and 4 subjects had prolonged (≥ 6 months) disease stabilization (SD). Both PRs and three prolonged SD occurred in adenoid cystic carcinoma (ACC) subjects with evidence of Notch1 pathway activation. Pharmacodynamic effects of brontictuzumab were seen in patients' blood and tumor. Conclusion Brontictuzumab was well tolerated at the MTD. The main toxicity was diarrhea, an on-target effect of Notch1 inhibition. An efficacy signal was noted in subjects with ACC and Notch1 pathway activation. ClinicalTrials.gov identifier NCT01778439.
Collapse
Affiliation(s)
- R Ferrarotto
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
| | - G Eckhardt
- Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, USA
| | - A Patnaik
- Phase I Medical Oncology Program, South Texas Accelerated Research Therapeutics (START), San Antonio, USA
| | - P LoRusso
- Yale School of Medicine, Experimental Therapeutics, New Haven, USA
| | - L Faoro
- OncoMed Pharmaceuticals Inc, Redwood City, USA
| | - J V Heymach
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - A M Kapoun
- OncoMed Pharmaceuticals Inc, Redwood City, USA
| | - L Xu
- OncoMed Pharmaceuticals Inc, Redwood City, USA
| | - P Munster
- Division of Hematology and Oncology, University of California San Francisco, San Francisco, USA
| |
Collapse
|
10
|
Hamilton E, Vidula N, Ma C, LoRusso P, Bagley R, Yu Z, Annett M, Weitzman A, Conlan M, Weise A. Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Calvo E, de Jonge M, Rasco D, Moreno V, Chang YW, Chiney M, Motwani M, Penugonda S, Petrich A, Ratain M, LoRusso P. First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Adams S, Hamilton E, Ott PA, Cho D, Kalinsky K, LoRusso P, Will M, Huels V, Benson B, Murias C, Arkenau HT. Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Probody™ therapeutics are novel, fully recombinant antibody prodrugs designed to remain relatively inactive in healthy tissue and to be specifically activated by proteases in the tumor microenvironment. In this way, Probody therapeutics may broaden the therapeutic window for effective but potentially toxic anticancer agents. CX-072 is a Probody therapeutic directed against programmed death-ligand 1 (PD-L1) for the treatment of cancer patients. In a first-in-human, open-label, multicenter, dose-escalation, 3+3 design, phase 1-2 study, PROCLAIM-CX-072 (PRObody CLinical Assessment In Man) (NCT03013491), 22 patients were enrolled in the phase 1 dose escalation portion. Twenty patients were evaluable per RECIST v1.1. Three patients had confirmed partial response (15%), including a 39-year-old woman with stage IV triple negative breast cancer (TNBC) treated with 10 mg/kg CX-072 monotherapy whose disease had progressed on one previous line of chemotherapy for metastatic disease. Metastatic sites included extensive nodal disease and skin/chest wall lesions. The tumor was negative for PD-L1 expression, was microsatellite stable, and had a low tumor mutational burden (4 mutations/megabase). Positive results from the phase 1 study suggest that additional exploration of treatment with CX-072 monotherapy in the TNBC patient population is warranted.
Dose expansion trial design: The phase 2 dose expansion part of the PROCLAIM-CX-072 study will include enrollment of TNBC patients with skin metastases. Key inclusion criteria for patients in the TNBC cohort are as follows: naive to immunotherapy (PD-1/PD-L1 and CTLA-4 inhibitors), approved immune checkpoint inhibitor agents not available, histologically confirmed triple negative (estrogen receptor–, progesterone receptor–, and human epidermal growth factor receptor-2–negative cancer per ASCO-CAP guidelines), previously treated with 1 to 3 systemic chemotherapy regimens, and locally advanced and recurrent skin or subcutaneous metastases not suitable for surgical resection or radiotherapy. Patients will receive doses of 10 mg/kg CX-072 intravenously every 2 weeks. Efficacy will be evaluated using RECIST v1.1 and immune-related RECIST criteria. Safety and tolerability will be assessed based on the incidence and severity of adverse events (categorized by NCI CTCAE criteria, v4.03) and relationship to study drug. Other analyses will include pharmacokinetics, incidence of anti-drug antibodies against CX-072, exploratory analysis for immune response, and CX-072 activation in the tumor.
PROBODY is a trademark of CytomX Therapeutics, Inc.
Citation Format: Adams S, Hamilton E, Ott PA, Cho D, Kalinsky K, LoRusso P, Will M, Huels V, Benson B, Murias C, Arkenau H-T. PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-31.
Collapse
Affiliation(s)
- S Adams
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - E Hamilton
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - PA Ott
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - D Cho
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - K Kalinsky
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - P LoRusso
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - M Will
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - V Huels
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - B Benson
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - C Murias
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - H-T Arkenau
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| |
Collapse
|
13
|
Yee D, Prat A, Sablin M, Iwata H, Johnston E, Bogenrieder T, Serra J, Hua H, LoRusso P. A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/- endocrine therapy), or non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx656.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Geretti E, Espelin C, Adiwijaya B, Coma S, Koncki Z, Sumner P, Dumont N, Garcia G, Bloom T, Janovsky J, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, Krop I, Miller K, Ma C, Munster P, Wickham T. Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- E Geretti
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - C Espelin
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - B Adiwijaya
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - S Coma
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Z Koncki
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P Sumner
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - N Dumont
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - G Garcia
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - T Bloom
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - J Janovsky
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - J Reynolds
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - K Campbell
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - V Moyo
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - I Molnar
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P LoRusso
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - I Krop
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - K Miller
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - C Ma
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - P Munster
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - T Wickham
- Merrimack Pharmaceuticals Inc., Cambridge, MA; Yale Cancer Center, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Washington University School of Medicine, St. Louis, MO; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| |
Collapse
|
15
|
LoRusso P, Miller K, Shields A, Saito K, Yoshida K, Aoyama T, Winkler R, Benedetti F, Lenz H. Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32953-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Higano CS, Berlin J, Gordon M, LoRusso P, Tang S, Dontabhaktuni A, Schwartz JD, Cosaert J, Mehnert JM. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2015; 33:450-62. [PMID: 25749986 DOI: 10.1007/s10637-015-0217-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Accepted: 02/05/2015] [Indexed: 12/27/2022]
Abstract
BACKGROUND Type 1 insulin-like growth factor receptor (IGF-IR) signaling is often dysregulated in cancer. Cixutumumab, a fully human IgG1 monoclonal antibody, blocks IGF-IR and inhibits downstream signaling. The current study determined the recommended dose, safety, and pharmacokinetic (PK) profile of weekly or every-2-week dosing of cixutumumab. PATIENTS AND METHODS Two open-label, multicenter phase I studies evaluated weekly (3-15 mg/kg) or every-2-weeks (6-15 mg/kg) dosing of cixutumumab in patients with advanced solid tumors. Serial blood samples for PK were collected up to 168-336 h (day 8-15) following the first administration of cixutumumab. Efficacy was evaluated as best overall tumor response. RESULTS A total of 24 and 16 patients were enrolled in the weekly and every-2-week dosing studies, respectively. Treatment-emergent adverse events (≥10%) included hyperglycemia, fatigue, anemia, nausea, and vomiting. Severe adverse events (AE) were infrequent; one serious AE (grade 3 electrocardiogram QT prolongation) was deemed possibly cixutumumab-related (10 mg/kg every-2-weeks). One death occurred due to disease progression (6 mg/kg weekly cohort). Maximum serum concentrations increased with dose. A maximum tolerated dose was not identified; pre-determined target serum minimum concentrations (60 μg/mL) were achieved with ≥6 mg/kg weekly and ≥10 mg/kg every-2-week dosing. Cixutumumab terminal elimination half-life is approximately a week (individual range, t1/2 = 4.58-9.33 days based upon 10 mg/kg every 2 weeks). Overall, stable disease was achieved in 25% of all patients. CONCLUSIONS Cixutumumab was associated with favorable safety and PK profiles. A dosing regimen of 10 mg/kg every 2 weeks was recommended for subsequent disease-focused clinical trials.
Collapse
Affiliation(s)
- C S Higano
- Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA,
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Papadopoulos K, Tolcher A, Kittaneh M, Patniak A, Rasco D, Chambers G, Newth G, Savage R, Hall T, Schwartz B, Kazakin J, LoRusso P. 389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Hendriks B, Shields A, Siegel B, Miller K, Munster P, Ma C, Campbell K, Moyo V, Wickham T, LoRusso P. PET/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies Variability of Liposomal Drug Delivery to Diverse Tumor Lesions in HER2-Positive Breast Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu068.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Traina T, Yardley D, Patel M, Schwartzberg L, Elias A, Gucalp A, Blaney M, Gibbons J, Hudis C, LoRusso P. A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu064.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Munster P, Krop IE, Miller K, Dhindsa N, Niyijiza C, Nielsen U, Odueyungbo A, Rajarethinam A, Marande M, Campbell K, Geretti E, Reynolds JG, Hendriks BS, Wickham T, Moyo V, LoRusso P. Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-29] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MM-302 is a novel antibody drug conjugate (ADC) combining PEGylated liposomal doxorubicin with anti-HER2 scFvs. MM-302 was designed to overcome the limitations associated with using anthracyclines in the treatment of HER2-positive breast cancer. Anthracyclines have been an effective backbone of breast cancer therapies for decades. However, cardiotoxicity issues associated with free anthracyclines have limited their effective use. While liposomal doxorubicin formulations have succeeded in reducing cardiotoxicity, they have failed to demonstrate clear-cut efficacy advantages. MM-302 specifically targets tumor cells overexpressing HER2 with minimal uptake into normal cells such as cardiomyocytes which express low levels of HER2. This Phase 1 study evaluates the safety of MM-302 in patients with HER2+ advanced breast cancer.
Methods: Patients aged ≥ 18 years with histologically confirmed HER2+ advanced breast cancer that have progressed or recurred on standard therapy or for which no standard therapy exists having measurable disease, adequate performance status, bone marrow reserve and organ function, were eligible for the study. A post-treatment biopsy was required. A 3 + 3 dose escalation design (8, 16, 30, 40 and 50 mg/m2 administered i.v. q4w) is used to identify a Phase 2 dose followed by expansion arms at 40 and 50 mg/m2 for a preliminary indication of activity. Secondary endpoints included determination of dose-limiting toxicity, adverse event(s), and PK of MM-302, as well as overall response and clinical benefit rates of MM-302.
Results: We report data from MM-302 dose levels (30, 40 and 50 mg/m2 as monotherapy) that are expected to be therapeutically relevant. Eight patients dosed at presumed sub-therapeutic dose levels of 8 and 16 mg/m2 were excluded from the efficacy analysis. Patients had received a median of 9.5 prior agents (range 3-19) in all settings. All patients had been treated with trastuzumab, 96% with prior taxanes, 67% lapatinib, 54% anthracyclines and 33% T-DM1. At the time of this analysis (n = 27), overall response rate was 17% (4 out of 24 evaluable patients) and the estimated median Progression Free Survival (PFS) was 5.7 months, with six patients still receiving treatment. Eight patients (30%) had a PFS of greater than 6.0 months. Neutropenia was the most common treatment-related grade 3/4 toxicity and occurred in 15% of patients. The most common adverse events include fatigue, nausea, vomiting, and decreased appetite. Constipation, stomatitis, headache and rash were also observed in greater than 20% of patients. No patients discontinued treatment for toxicity. There was no protocol defined cardiotoxicity observed across all dose cohorts and five patients have had cumulative anthracycline exposure exceeding 550 mg/m2 without a reduction in left ventricular ejection fraction.
Conclusion: Overall MM-302 appears to be well tolerated with promising activity in this ongoing trial. Further development is continuing combining MM-302 with trastuzumab and/or cyclophosphamide. In addition, we are evaluating the use of PET imaging to correlate liposomal tumor deposition as an additional potential patient preselection strategy.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-29.
Collapse
Affiliation(s)
- P Munster
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - IE Krop
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - K Miller
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - N Dhindsa
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - C Niyijiza
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - U Nielsen
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - A Odueyungbo
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - A Rajarethinam
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - M Marande
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - K Campbell
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - E Geretti
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - JG Reynolds
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - BS Hendriks
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - T Wickham
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - V Moyo
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| | - P LoRusso
- Helen Diller Family Compreshensive Cancer Center, UCSF, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Merrimack Pharmaceuticals, Inc, Cambridge, MA; Karmanos Cancer Institute, Detroit, MI
| |
Collapse
|
21
|
Hunsberger S, Rubinstein L, Boerner SA, LoRusso P. Response. J Natl Cancer Inst 2013; 105:993-4. [DOI: 10.1093/jnci/djt126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 2013; 24:784-91. [PMID: 23104723 PMCID: PMC3574548 DOI: 10.1093/annonc/mds511] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2012] [Revised: 07/23/2012] [Accepted: 08/27/2012] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS Patients with advanced solid tumors received three weekly AVE1642 dosed at 6 mg/kg, chosen following previous study, with 75 (cohort A) or 100 mg/m(2) (B) docetaxel, 1250 mg/m(2) gemcitabine/100 mg erlotinib (C1), or 60 mg/m(2) doxorubicin (D1). Blood samples were assayed for PK, IGFs, and IGF-BP3. RESULTS Fifty-eight patients received 317 AVE1642 infusions. The commonest adverse events were diarrhea (37/58 patients), asthenia (34/58), nausea (30/58), and stomatitis (21/58). Dose-limiting toxic effects in cohorts C1 (diarrhea) and D1 (neutropenia) prompted addition of cohorts C2 (1000 mg/m(2) gemcitabine/75 mg erlotinib) and D2 (50 mg/m(2) doxorubicin). Grade 3-4 hyperglycemia (three cases) accompanied steroid premedication for docetaxel administration. No PK interactions were detected. There were three partial responses in cohorts B (melanoma) and C (leiomyosarcoma, two cases) and 22 stabilizations ≥12 weeks, giving a control rate of 25/57 (44%). On treatment IGF-II rose by 68 ± 25 ng/ml in patients discontinuing treatment <12 weeks, and fell by 55.5 ± 21 ng/ml with disease control (P < 0.001). CONCLUSION AVE1642 was tolerable with 75-100 mg/m(2) docetaxel and 1000 mg/m(2) gemcitabine/75 mg erlotinib, achieving durable disease control in 44%, with an association between IGF-II and response.
Collapse
Affiliation(s)
- V M Macaulay
- Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LE, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Sci Transl Med 2012; 4:128ra39. [DOI: 10.1126/scitranslmed.3003651] [Citation(s) in RCA: 872] [Impact Index Per Article: 72.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
24
|
Haluska P, Huang J, Lam B, Liang M, Huang W, LoRusso P, Menefee ME, LaVallee T, Yao Y, Viner J. MEDI-573 as a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase I PK/PD, safety data, and disease linkage studies in breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.271] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
271 Background: MEDI-573 is a dual-targeting human antibody that neutralizes IGF-I/-II ligands and inhibits IGF-1R and insulin receptor-A (IR-A) signaling pathways, which play a role in breast and other epithelial cancers. By sparing IR-B and its hybrid receptors, MEDI-573 is expected to achieve antitumor activity without perturbing glucose homeostasis. Methods: In a 3 + 3 dose-escalation trial ( NCT00816361 ), patients with advanced solid tumors, KPS ≥ 60, received MEDI-573 as a weekly 1-hr IV infusion at 0.5, 1.5, 5, 10, or 15 mg/kg every 21 days. Objectives included determination of MTD, safety profile, pharmacokinetics (PK), pharmacodynamics, and tumor response. In a separate biomarker study, mRNA expression of IR-A and IR-B was compared in HR+/HER- breast cancers. Results: Patients included 13M/12F (17 evaluable for efficacy at data cutoff); median age 59 yrs (range 37-78). No DLTs, drug-related SAEs, or significant toxicity patterns were reported. Forty-five AEs were considered treatment-related (% of patients): decreased appetite (28%), fatigue (24%), nausea (20%), diarrhea (16%), and anemia (12%). Hyperglycemia occurred in 2 patients, 1 with evidence of prestudy insulin resistance. No other significant changes in plasma glucose levels occurred. MEDI-573 had dose-proportionality, with AUC of 415 ± 165, 597 ± 298, and 1940 ± 904 d*μg/mL at 5, 10, and 15 mg/kg, respectively. Suppression of free IGF-1 and -2 was fully achieved at doses ≥ 5 mg/kg. Stable disease spanning ≥ 12 wks (range 12-36+) was seen in 6/17 patients. No antidrug antibodies were reported. In a study to identify breast cancer subsets that are dependent on IGF signaling, the IR-A:IR-B ratio was significantly higher in HR+/HER2- breast cancer than matched adjacent normal tissues and in proliferative luminal B than in luminal A breast cancer. Conclusions: MEDI-573 showed acceptable safety and favorable PK profiles without significant changes in glucose levels. The IR-A:IR-B ratio supports a biomarker approach for MEDI-573 patient stratification. A biomarker-rich phase Ib/II study of MEDI-573 with an aromatase inhibitor in patients with advanced HR+/HER2- breast cancer opens in 2011.
Collapse
Affiliation(s)
- P. Haluska
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - J. Huang
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - B. Lam
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - M. Liang
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - W. Huang
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - P. LoRusso
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - M. E. Menefee
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - T. LaVallee
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - Y. Yao
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| | - J. Viner
- Mayo Clinic, Rochester, MN; MedImmune, LLC, Gaithersburg, MD; Karmanos Cancer Institute, Detroit, MI; Mayo Clinic, Jacksonville, FL
| |
Collapse
|
25
|
Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DSA. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer 2011; 105:44-52. [PMID: 21629245 PMCID: PMC3137402 DOI: 10.1038/bjc.2011.182] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Background: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies. Methods: Patients with advanced gastrointestinal malignancies who had failed prior therapies received brivanib (320, 600 or 800 mg daily) plus cetuximab (400 mg m–2 loading dose then 250 mg m–2 weekly). Assessments included adverse events, PK, tumour response, 2[18F]fluoro-2-deoxyglucose positron-emitting tomography and K-Ras mutation analyses. Results: Toxicities observed were manageable; the most common treatment-related toxicities (>10% of patients) were fatigue, diarrhoea, anorexia, increase in aspartate aminotransferase and alanine aminotransferase, acneiform dermatitis, headache, mucosal inflammation, nausea, dry skin, vomiting, hypertension, pruritus, proteinuria and weight loss. Of 62 patients, 6 (9.7%) had objective radiographic partial responses, with an overall response rate of 10%. Median duration of response was 9.2 months; median progression-free survival was 3.9 months. Conclusions: The acceptable toxicity profile and efficacy of brivanib observed in this study were promising. These findings are being further evaluated in a phase III study of brivanib plus cetuximab vs cetuximab alone in patients previously treated with combination chemotherapy for K-Ras wild-type advanced metastatic colorectal cancer.
Collapse
Affiliation(s)
- C R Garrett
- Department of Gastrointestinal Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Berlin J, Keedy VL, Janne PA, Yee L, Rizvi NA, Jin X, Copigneaux C, Hettmann T, Beaupre DM, LoRusso P. A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Weekes CD, LoRusso P, Ramakrishnan V, Shih LM, Darbonne WC, Hegde P, Xin Y, Yu R, Xiang H, Brachmann RK, Patnaik A. A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3050] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Dickson MA, LoRusso P, Sausville EA, Rao N, Kobayashi E, Kurman MR, Akinaga S, Schwartz GK. Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, Courtney RD, Randolph S, Shapiro G. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3100] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Sosman JA, Adjei AA, LoRusso P, Michael SA, Dy GK, Bowditch A, Chmielowski B, Lee S, Walker RM, Faucette S, Izmailova ES, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps145] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Sausville EA, LoRusso P, Carducci MA, Barker PN, Agbo F, Oakes P, Senderowicz AM. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3058] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Cho DC, Heath EI, Cleary JM, Kwak EL, Gandhi L, Lawrence DP, Zack C, Teofilovici F, Bradley R, Karol MD, Shapiro G, LoRusso P. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3051] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Camidge DR, Bang Y, Kwak EL, Shaw AT, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Wilner KD, Costa DB, Shapiro G, LoRusso P, Stephenson P, Tang Y, Ruffner K, Clark JW. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2501] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Darbonne WC, Du X, Dhawan P, Hartley D, Tarrant J, Taylor H, Cain G, Shih LM, Brachmann RK, Phung Q, Weekes CD, LoRusso P, Patnaik A, Xiang H, Ramakrishnan V. Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13598] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Cervantes A, Alsina M, Tabernero J, Infante JR, LoRusso P, Shapiro G, Paz-Ares LG, Falzone R, Hill J, Cehelsky J, White A, Toudjarska I, Bumcrot D, Meyers R, Hinkle G, Svrzikapa N, Sah DW, Vaishnaw A, Gollob J, Burris HA. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3025] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Gadgeel SM, Ruckdeschel JC, Wozniak AJ, Chen W, Hackstock D, Galasso C, Burger A, Ivy SP, LoRusso P, Edelman MJ. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7564] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Naing A, LoRusso P, Fu S, Hong DS, Anderson PM, Benjamin RS, Ludwig JA, Chen HX, Doyle LA, Kurzrock R. Cixutumumab combined with temsirolimus in patients with refractory Ewing’s sarcoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Shapiro G, LoRusso P, Kwak EL, Cleary JM, Musib L, Jones C, de Crespigny A, Belvin M, McKenzie M, Gates MR, Chan IT, Bendell JC. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3005] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Maitah M, Ali S, LoRusso P, Sarkar FH, Gadgeel SM. The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10537] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Sarantopoulos J, Lenz H, LoRusso P, Shibata S, Kummar S, Mulkerin D, Ramanathan RK, Mita MM, O'Rourke P, Remick SC, Goel S, Gutierrez M, Ramalingam SS, Murgo A, Davies AM, Mani S, Boni J, Shapiro M, Ivy SP, Takimoto CH. Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Von Hoff DD, LoRusso P, Demetri GD, Weiss GJ, Shapiro G, Ramanathan RK, Ware JA, Raja R, Jin J, Levy GG, Mazina KE, Wagner AJ. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3052] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Gupta M, LoRusso P, Burris HA, Wang B, Joshi A, Tong YB, Chu Y, Girish S. Pharmacokinetic and pathophysiologic covariates influencing treatment outcomes with T-DM1 in patients with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.633] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
LoRusso P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, Boerner SA, Smith DW, Pilat MJ, Zhang J, Chen AP, Nechiporchik N, Parchment RE. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3000] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Chiorean EG, Sausville EA, Heath EI, Weise A, Gomez-Navarro J, Venkatakrishnan K, Sankoh S, Wu J, Corvez M, LoRusso P. Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
LoRusso P, Chiorean EG, Heath E, Weise A, Foley M, Olivo YS, Chi X, Corvez M, Venkatakrishnan K, Sausville E. Abstract P3-14-20: Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p3-14-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Objectives: TAK-285 is a novel, orally active, dual HER2/EGFR inhibitor. Nonclinical data show that TAK-285 has high selectivity and specificity for binding to HER family kinases, and has demonstrated anti-tumor activity in a BT-474 mouse xenograft model of breast cancer. Nonclinical data also indicate that TAK-285 is not a substrate for the efflux transporters P-gp and BCRP and penetrates an intact blood-brain barrier in rats. This phase 1 dose-escalation study in patients with advanced cancer aimed to determine the safety and pharmacokinetic (PK) profile.
Methods: Adults had advanced histologically confirmed non-hematologic malignancies, life expectancy >12 weeks, adequate bone marrow, liver and renal function, ECOG PS 0-2, and were refractory to other treatments. Oral TAK-285 was escalated from 50 to 500 mg QD or BID for 21 or 28 consecutive days of a 28-day cycle until disease progression or unacceptable toxicity was observed.
Results: At the data cut-off of 04/23/10, the dose-escalation portion was complete, and the RP2D expansion cohort is ongoing. Preliminary data from the dose-escalation cohorts are reported. 43 patients (median age 60 years [43-76]) were enrolled: 30% ≥65 years, 51% female, and 86% white. Dose levels were 50 mg QD (N=4), 50 mg BID (N=7), and 75 mg BID (N=6) on d 1-21; and 150 mg (N=6), 225 mg (N=4), 325 mg (N=3), 400 mg (N=6), and 500 mg (N=7) BID on d 1-28. Median duration of exposure across all cohorts was 52 days (3-267). Four patients experienced a DLT in Cycle 1: 1 patient (50 mg BID) had Grade 3 pancreatitis; 1 patient (150 mg BID) had Grade 3 chest pain and Grade 3 hypoxia; 1 patient (500 mg BID) had Grade 3 increased ALT; and 1 patient (500 mg BID) had Grade 3 diarrhoea and Grade 3 hypokalaemia. The MTD was 400 mg BID d 1-28. 30 patients (70%) discontinued TAK-285, primarily due to disease progression (n=19, 44%) or an AE (n=9, 21%). Most frequent AEs were fatigue (37%), diarrhoea (35%), nausea (26%), anorexia (21%), vomiting (16%), and elevated AST (16%). 58% of patients had a drug-related AE; the most frequent were diarrhoea (21%), fatigue (19%), and rash (includes rash, rash maculo-papular and rash macular; 12%). 35% of patients had a grade 3/4 AE; the most common were hypokalaemia (7%), ileus, abdominal pain, and hypoxia (5% each). Grade 3/4 AEs related to TAK-285 were the DLTs in Cycle 1 and Grade 4 rhabdomyolysis in 1 patient (400 mg BID, d 1-28) in Cycle 3. 42% of patients experienced a serious AE (SAE); the only SAE seen in >1 patient was ileus (n=2). 4 (9%) patients had fatal AEs; none were considered related to TAK-285. Absorption was fast: plasma concentrations peaked 2-3 hours post-dose. Steady-state plasma exposures increased with dose in a greater than dose-proportional manner, with PK steady-state achieved by Day 8. Accumulation was noted with BID dosing (mean accumulation ratio, 2.4 at MTD); there was moderate fluctuation in plasma concentrations over the steady-state dosing interval (mean Cmax:Cmin ratio, 2.4 at MTD).
Conclusions: The MTD for TAK-285 was 400 mg BID d 1-28. The RP2D cohort is ongoing and includes CSF collection to assess the CNS distribution of TAK-285. Updated safety as well as efficacy data for the dose escalation cohorts will be presented.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-14-20.
Collapse
Affiliation(s)
- P LoRusso
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - EG Chiorean
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - E Heath
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - A Weise
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - M Foley
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - YS Olivo
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - X Chi
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - M Corvez
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - K Venkatakrishnan
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| | - E. Sausville
- Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Millennium Pharmaceuticals Inc., Cambridge, MA; University of Maryland Greenebaum Cancer Center, Baltimore
| |
Collapse
|
46
|
LoRusso P. 6 Challenges in clinical development of stem-cell therapy. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71709-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
47
|
Tolcher A, Papadopolous K, Patniak A, Heath E, Weise A, Prokop T, Morrone S, Zanghi J, Keer H, LoRusso P. 381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72088-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
48
|
Gupta S, Alqwasmi A, Hunsberger S, Rubinstein L, Ivy P, Royds R, LoRusso P. 363 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72070-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
49
|
Shimizu T, Tolcher A, LoRusso P, Papadopoulos K, Patnaik A, Smith L, Keegan M. 364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72071-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
Fairbrother W, LoRusso P, Wagner A, Budha N, Darbonne W, Shin Y, Wong H, Chan I, Ware J, Eckhardt S. 393 Phase I pharmacokinetics and pharmacodynamics of GDC-0152, a novel IAP protein antagonist, administered to patients with locally advanced or metastatic malignancies. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72100-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|